Key result
Live oral AdV-4 and AdV-7 vaccine induced durable antibody responses, with 0% of subjects showing waning neutralizing antibodies against AdV-4 and <5% against AdV-7 at 6 years post-vaccination.
Why the study?
The safety and antibody response of the live oral AdV-4 and AdV-7 vaccine are established, but the long-term immunity of vaccination has not been studied.
Does the live oral AdV-4 and AdV-7 vaccine induce durable antibody responses over 6 years in vaccinated subjects?
Population
Subjects co-administered live oral AdV-4 and AdV-7 vaccine in 2011
Design
Cohort study
Follow-up
6 years
Authors
Loading...
Supports durable AdV-4/7 protection in military recruits; leaves open broader applicability and outcomes beyond 6 years.
Cohort
Does the live oral AdV-4 and AdV-7 vaccine induce durable antibody responses over 6 years in vaccinated subjects?
The live oral AdV-4 and AdV-7 vaccine induces durable, long-term neutralizing antibody responses up to 6 years post-vaccination.
Collins et al. (2020) conducted a cohort in Adenovirus Type 4 and Type 7 infection. Live oral AdV-4 and AdV-7 vaccine was evaluated on Duration of the antibody response (neutralizing antibody titers). Live oral AdV-4 and AdV-7 vaccine induced durable antibody responses, with 0% of subjects showing waning neutralizing antibodies against AdV-4 and <5% against AdV-7 at 6 years post-vaccination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: